BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

7390

543434

SUPRIYA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Supriya Lifescience performance

Today’s low

Today’s high

₹ 778.10 ₹ 817.70
₹ 785.00

52 week low

52 week high

₹ 556.15 ₹ 842.00
₹ 785.00

Open Price

₹ 778.10

Prev. Close

₹ 785.00

Volume (Shares)

228717.00

Total traded value

₹ 1795.42

Upper Circuit

₹ 942.00

Lower Circuit

₹ 628.00

info

Supriya Lifescience Share Price Update

As of the latest trading session, Supriya Lifescience share price is currently at ₹ 812.55, which is up by ₹ 27.54 from its previous closing. Today, the stock has fluctuated between ₹ 778.10 and ₹ 817.70. Over the past year, Supriya Lifescience has achieved a return of 24.60 %. In the last month alone, the return has been 6.56 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Supriya Lifescience fundamentals


  • Market cap (Cr)

    6,317.90

  • P/E Ratio (TTM)

    35.05

  • Beta

    1.84

  • Book Value / share

    123.84

  • Return on equity

    20.74%

  • EPS (TTM)

    22.13

  • Dividend yield

    0.13%

  • Net profit/quarter (Cr)

    34.79

info icon alternate text
  • Market cap (Cr)

    6,315.90

  • P/E Ratio (TTM)

    35.05

  • Beta

    1.75

  • Book Value / share

    123.84

  • Return on equity

    20.74%

  • EPS (TTM)

    22.13

  • Dividend yield

    0.13%

  • Net profit/quarter (Cr)

    34.79

info icon alternate text

Supriya Lifescience Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 145.07
Operating Expense 100.33
Net Profit 34.79
Net Profit Margin (%) 23.98
Earnings Per Share (EPS) 4.32
EBITDA 54.37
Effective Tax Rate (%) 26.61
Particulars MAR 2025 (Values in Cr)
Revenue 184.11
Operating Expense 123.03
Net Profit 50.38
Net Profit Margin (%) 27.36
Earnings Per Share (EPS) 6.29
EBITDA 70.56
Effective Tax Rate (%) 21.35
Particulars DEC 2024 (Values in Cr)
Revenue 185.65
Operating Expense 125.17
Net Profit 46.78
Net Profit Margin (%) 25.19
Earnings Per Share (EPS) 5.82
EBITDA 68.05
Effective Tax Rate (%) 25.24
Particulars SEP 2024 (Values in Cr)
Revenue 166.10
Operating Expense 106.56
Net Profit 46.15
Net Profit Margin (%) 27.78
Earnings Per Share (EPS) 5.71
EBITDA 67.23
Effective Tax Rate (%) 25.65
Particulars JUN 2024 (Values in Cr)
Revenue 160.63
Operating Expense 103.08
Net Profit 44.64
Net Profit Margin (%) 27.79
Earnings Per Share (EPS) 5.54
EBITDA 64.77
Effective Tax Rate (%) 25.31
Particulars MAR 2025 (Values in Cr)
Revenue 696.49
Operating Expense 457.82
Net Profit 187.96
Net Profit Margin (%) 26.98
Earnings Per Share (EPS) 23.35
EBITDA 270.61
Effective Tax Rate (%) 24.35
Particulars MAR 2024 (Values in Cr)
Revenue 570.37
Operating Expense 415.32
Net Profit 119.11
Net Profit Margin (%) 20.88
Earnings Per Share (EPS) 14.80
EBITDA 183.61
Effective Tax Rate (%) 28.11
Particulars MAR 2023 (Values in Cr)
Revenue 460.94
Operating Expense 346.94
Net Profit 89.86
Net Profit Margin (%) 19.49
Earnings Per Share (EPS) 11.16
EBITDA 138.39
Effective Tax Rate (%) 27.23
Particulars MAR 2022 (Values in Cr)
Revenue 530.05
Operating Expense 330.38
Net Profit 151.81
Net Profit Margin (%) 28.64
Earnings Per Share (EPS) 18.86
EBITDA 221.57
Effective Tax Rate (%) 26.75
Particulars MAR 2021 (Values in Cr)
Revenue 391.25
Operating Expense 228.91
Net Profit 123.59
Net Profit Margin (%) 31.58
Earnings Per Share (EPS) 16.89
EBITDA 178.15
Effective Tax Rate (%) 26.13
Particulars MAR 2025 (Values in Cr)
Book Value / Share 123.84
ROE % 20.74
ROCE % 27.43
Total Debt to Total Equity 0.01
EBITDA Margin 34.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 101.31
ROE % 15.73
ROCE % 22.05
Total Debt to Total Equity 0.02
EBITDA Margin 28.85
Particulars MAR 2023 (Values in Cr)
Book Value / Share 86.91
ROE % 13.67
ROCE % 18.43
Total Debt to Total Equity 0.04
EBITDA Margin 26.79
Particulars MAR 2022 (Values in Cr)
Book Value / Share 76.50
ROE % 34.34
ROCE % 41.97
Total Debt to Total Equity 0.11
EBITDA Margin 37.65
Particulars MAR 2021 (Values in Cr)
Book Value / Share 36.70
ROE % 59.18
ROCE % 55.75
Total Debt to Total Equity 0.37
EBITDA Margin 41.34
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 79.15
Total Assets 1112.31
Total Liabilities 1112.31
Total Equity 996.76
Share Outstanding 80482800
Price to Book Ratio 5.92
Return on Assets (%) 16.89
Return on Capital (%) 18.86
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 74.95
Total Assets 921.44
Total Liabilities 921.44
Total Equity 815.36
Share Outstanding 80482800
Price to Book Ratio 3.27
Return on Assets (%) 12.92
Return on Capital (%) 14.61
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 157.58
Total Assets 820.27
Total Liabilities 820.27
Total Equity 699.45
Share Outstanding 80482800
Price to Book Ratio 2.19
Return on Assets (%) 10.95
Return on Capital (%) 12.55
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 227.90
Total Assets 734.76
Total Liabilities 734.76
Total Equity 615.68
Share Outstanding 80482800
Price to Book Ratio 6.44
Return on Assets (%) 20.66
Return on Capital (%) 23.83
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 89.27
Total Assets 445.46
Total Liabilities 445.46
Total Equity 268.58
Share Outstanding 73183530
Price to Book Ratio 0.00
Return on Assets (%) 27.74
Return on Capital (%) 36.49
Particulars MAR 2025 (Values in Cr)
Net Income 248.48
Cash from Operations 223.85
Cash from Investing -152.24
Cash from Financing -8.23
Net change in Cash 4.19
Free Cash Flow 386.23
Particulars MAR 2024 (Values in Cr)
Net Income 165.69
Cash from Operations 150.95
Cash from Investing -173.57
Cash from Financing -22.35
Net change in Cash -82.62
Free Cash Flow 296.60
Particulars MAR 2023 (Values in Cr)
Net Income 123.48
Cash from Operations 94.28
Cash from Investing -123.65
Cash from Financing -10.27
Net change in Cash -70.32
Free Cash Flow 202.19
Particulars MAR 2022 (Values in Cr)
Net Income 207.24
Cash from Operations 109.76
Cash from Investing -59.82
Cash from Financing 149.65
Net change in Cash 138.63
Free Cash Flow 169.66
Particulars MAR 2021 (Values in Cr)
Net Income 167.30
Cash from Operations 105.88
Cash from Investing -46.80
Cash from Financing -14.51
Net change in Cash 14.57
Free Cash Flow 154.12
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 32.55 13.29 1.78 249.44 30.00 / 68.00
BLISS GVS PHARMA LTD 156.60 15.52 1.57 1654.47 105.05 / 190.65
CIPLA LTD 1501.65 22.29 3.68 121298.96 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 275.65 7.76 2.23 811.27 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2624.25 46.95 22.78 44456.38 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 32.55 17.69 5.14 249.44 30.00 / 68.00
AMRUTAJAN HEALTH LTD 724.70 38.43 6.41 2095.15 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9535.45 112.73 30.94 23838.63 6222.35 / 10653.05
BLISS GVS PHARMA LTD 156.60 23.44 1.56 1654.47 105.05 / 190.65

Supriya Lifescience shareholding pattern

Holding

Others
21.01%
Promoter Holdings
68.29%
FII
5.45%
DII
5.22%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Satish Waman Wagh 5.4441205E7 (67.64%) Shareholding of Promoter and Promoter Group
Aditya Birla Sun Life Insurance Company Limited 1727407.0 (2.15%) Public Shareholding
Cohesion Mk Best Ideas Sub-trust 1710816.0 (2.13%) Public Shareholding
Smita Satish Wagh 321750.0 (0.4%) Shareholding of Promoter and Promoter Group
Shivani Satish Wagh 102375.0 (0.13%) Shareholding of Promoter and Promoter Group
Saloni Satish Wagh 102375.0 (0.13%) Shareholding of Promoter and Promoter Group
Satish Waman Wagh Partner Representing Supriyapharmaceuticals 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Arun Waman Wagh 110.0 (0.0%) Shareholding of Promoter and Promoter Group

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

News

Left Arrow
Right Arrow

Supriya Lifescience Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
785.00 1.04 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 756.70
  • 26 Days 731.50
  • 10 Days 748.60
  • 50 Days 715.70
  • 12 Days 746.10
  • 100 Days 702.30
  • 20 Days 737.20
  • 200 Days 677.00
774.25 PIVOT

First Support

748.70

First Resistance

802.45

Second Support

720.50

Second Resistance

828.00

Third Support

694.95

Third Resistance

856.20

RSI

67.79

ADX

16.00

MACD

14.60

Williams % R

-19.23

Commodity Channel Index (CCI)

182.74

Date

2025-10-31

Week

158260.00

Same Day

313724.00

Month

112281.00

1 Year

1.85

3 Year

1.19

Over 1 Month

6.56%

down

Over 1 Year

24.60%

down

Over 3 Months

17.48%

down

Over 3 Years

39.37%

down

Over 6 Months

20.42%

down

Over 5 Years

0.00%

down

Supriya Lifescience Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
04 Sep 2025 1.0 Final 05 Sep 2025 Equity shares
20 Sep 2024 0.8 Final 21 Sep 2024 Equity shares
15 Sep 2023 0.6 Final 15 Sep 2023 Equity shares
01 Sep 2022 0.6 Final 02 Sep 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
Dividend date Dividend amount Dividend type Record date Instrument type
04 Sep 2025 1.0 Final 05 Sep 2025 Equity shares
20 Sep 2024 0.8 Final 21 Sep 2024 Equity shares
15 Sep 2023 0.6 Final 15 Sep 2023 Equity shares
01 Sep 2022 0.6 Final 02 Sep 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Supriya Lifescience Share Price

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'. The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007. Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai.

The Company commenced operations in April, 2008. It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs). The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. The company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.

The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The company's products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.

The company's business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022.

In December 2021, the Company came up with an Initial Public Offer aggregating to Rs 700 crore out of which Rs 500 crore was Offer for Sale (OFS) and Rs 200 was Fresh Issue.

In 2022-23, the Company acquired a manufacturing facility with the objective of commissioning backward integration projects. The Company initiated the construction of a new warehouse and administration block, which comprises a new quality control and assurance lab. It acquired plot of land at Isambe near Patalganga for capacity expansion.

In 2025, the Company commissioned state-of-the-art Module E production block at Lote Parshuram, increasing the installed capacity
from 597 KLPD to 932 KLPD.

Parent organization Indian Private
NSE symbol SUPRIYA
Founded 2008
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of [-]?

Answer Field

[-] share price is for NSE ₹ [-] & for BSE ₹ [-] as on Nov 04 2025 10:09 AM.

What is the Market Cap of [-] Share?

Answer Field

The market cap of [-] for NSE ₹ [-] & for BSE ₹ [-] as on Nov 04 2025 10:09 AM.

What is the 52 Week High and Low of [-]?

Answer Field

The 52 Week High and Low of [-] for NSE is ₹ [-] and ₹ [-] and for BSE is ₹ [-] and ₹ [-].

What is 1 year return for [-]?

Answer Field

The 1 year returns on the stock has been [-]%.

What is the P/E Ratio of [-] Share?

Answer Field

As on Nov 04 2025 10:09 AM the price-to-earnings (PE) ratio for [-] share is 35.05.

What is the PB ratio of [-] Share?

Answer Field

As on Nov 04 2025 10:09 AM, the price-to-book (PB) ratio for [-] share is 123.84.

How to Buy [-] Share on Bajaj Broking App?

Answer Field

To buy [-] shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “[-]”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59